

Olaparib SOLO-2

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects



Other adjustments



Long term plateau in the PFS curve



Olaparib SOLO-2

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies

Therapeutic Indication: Maintenance therapy in relapsed high-grade cancer of the ovaries, fallopian tubes and peritoneum with BRCA mutations after previous treatment and in whom platinum-based chemotherapy has reduced or cleared the cancer

Experimental Arm: Olaparib

Control Arm: Placebo



